title: Clinical impact of in-stent late loss after drug-eluting coronary stent implantation.
abstract: OBJECTIVE
  Controversy exists about the clinical significance of in-stent late loss (ISLL) after drug-eluting stent (DES) implantation. We sought to clarify whether ISLL after DES implantation is related to a potential clinical impact.
  
  
  RESULTS
  We included in a meta-regression analysis 21 trials (8641 patients) that randomly compared DES with bare-metal stents (BMS). We evaluated the relationship between angiographic behaviour of DES and the clinical impact of using DES instead of BMS in each trial using meta-regression techniques, weighting by the number of patients included in each trial. Mean ISLL in patients allocated to DES and DeltaISLL (difference in ISLL in patients allocated to BMS and DES) were used as angiographic parameters of efficacy of DES. The number of patients needed to be treated (NNT) to prevent one target lesion revascularization (TLR) was used to quantify the clinical impact of using DES instead of BMS. There was a significant relationship between mean ISLL in patients allocated to DES and the clinical benefit of using DES instead of BMS, as measured with the NNT for TLR: NNT for TLR = 6.2 + 18.4 [ISLL-DES] (R = 0.62; P = 0.007). Therefore, a 0.1 mm increase in mean ISLL-DES was associated with a 1.8 increase in NNT for TLR. There was also a significant association between the degree of inhibition of neointimal hyperplasia of DES in comparison with BMS with the NNT for TLR: NNT for TLR = 17.1-11.8 [DeltaISLL] (R = 0.61; P = 0.008). Therefore, a 0.1 mm reduction in ISLL by using DES instead of BMS was associated with a 1.2 decrease in mean NNT for TLR.
  
  
  CONCLUSIONS
  There is a strong and significant association between the degree of inhibition of neointimal formation with the use of DES and the clinical impact of using DES instead of BMS.
authors.affiliation: Department of Interventional Cardiology, University Hospital La Paz, Paseo La Castellana, 261, 28046 Madrid, Spain. raulmorenog@terra.es
authors.forename: Raúl
authors.initials: R
authors.lastname: Moreno
authors.forename: Cristina
authors.initials: C
authors.lastname: Fernandez
authors.forename: Angel
authors.initials: A
authors.lastname: Sanchez-Recalde
authors.forename: Guillermo
authors.initials: G
authors.lastname: Galeote
authors.forename: Luis
authors.initials: L
authors.lastname: Calvo
authors.forename: Fernando
authors.initials: F
authors.lastname: Alfonso
authors.forename: Rosana
authors.initials: R
authors.lastname: Hernandez
authors.forename: Rosa
authors.initials: R
authors.lastname: Sánchez-Aquino
authors.forename: Dominick J
authors.initials: DJ
authors.lastname: Angiolillo
authors.forename: Sergio
authors.initials: S
authors.lastname: Villarreal
authors.forename: Carlos
authors.initials: C
authors.lastname: Macaya
authors.forename: Jose L
authors.initials: JL
authors.lastname: Lopez-Sendon
mesh_terms: D023903:Coronary Restenosis / Q000517:prevention & control*; D003692:Delayed-Action Preparations; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives; D015607:Stents; D016559:Tacrolimus / Q000008:administration & dosage; D050257:Tubulin Modulators / Q000008:administration & dosage
chemical_list: D003692:Delayed-Action Preparations; D007166:Immunosuppressive Agents; D050257:Tubulin Modulators; C489443:zotarolimus; D017239:Paclitaxel; D020123:Sirolimus; D016559:Tacrolimus